Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study)

Allan L. Klein, Richard W. Asinger, Ian W. Black, Ravin Davidoff, Raimund Erbel, Jonathan L. Halperin, David A. Orsinelli, Thomas R. Porter, Marcus F. Stoddard, Kristopher Arheart, Richard A. Grimm, R. Daniel Murray

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Patients with atrial fibrillation (AF) undergoing cardioversion are at an increased risk of cardioembolic stroke and require anticoagulation. The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Multicenter Study is a randomized clinical trial of patients undergoing electrical cardioversion of AF of >2 days' duration comparing a transesophageal-guided strategy (TEE) with brief anticoagulation to the conventional anticoagulation strategy. Patients randomly assigned to the TEE- guided strategy receive therapeutic anticoagulation before TEE and cardioversion, followed by 4 weeks of anticoagulation. Patients with thrombus imaged by TEE have postponement of cardioversion, continue anticoagulation for 3 weeks, and undergo a repeat TEE. Conventional strategy patients receive 3 weeks of anticoagulation before cardioversion, followed by 4 weeks of anticoagulation after cardioversion. The primary end point events are ischemic stroke, transient ischemic attack, and systemic embolization for an 8-week period from enrollment. Secondary end points are major and minor bleeding, all-course mortality, successful return to and maintenance of sinus rhythm, and cost effectiveness. Analysis is based on the intention-to-treat principle. The anticipated rates of embolism of 2.9% for conventional strategy and 1.2% for the TEE-guided strategy are based on published research and the completed pilot study. The ACUTE Multicenter Study will randomize therapy and follow an estimated 3,000 patients from 65 study sites to determine the relative efficacy of the TEE-guided and conventional approaches to electrical cardioversion for patients in AF. The results of this investigation will have important clinical implications for the management of patients with AF undergoing electrical cardioversion.

Original languageEnglish
Pages (from-to)877-883
Number of pages7
JournalAmerican Journal of Cardiology
Volume81
Issue number7
DOIs
StatePublished - Apr 1 1998
Externally publishedYes

Fingerprint

Electric Countershock
Transesophageal Echocardiography
Multicenter Studies
Clinical Trials
Atrial Fibrillation
Stroke
Transient Ischemic Attack
Embolism
Cost-Benefit Analysis
Thrombosis
Randomized Controlled Trials
Maintenance
Hemorrhage

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study). / Klein, Allan L.; Asinger, Richard W.; Black, Ian W.; Davidoff, Ravin; Erbel, Raimund; Halperin, Jonathan L.; Orsinelli, David A.; Porter, Thomas R.; Stoddard, Marcus F.; Arheart, Kristopher; Grimm, Richard A.; Murray, R. Daniel.

In: American Journal of Cardiology, Vol. 81, No. 7, 01.04.1998, p. 877-883.

Research output: Contribution to journalArticle

Klein, AL, Asinger, RW, Black, IW, Davidoff, R, Erbel, R, Halperin, JL, Orsinelli, DA, Porter, TR, Stoddard, MF, Arheart, K, Grimm, RA & Murray, RD 1998, 'Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study)', American Journal of Cardiology, vol. 81, no. 7, pp. 877-883. https://doi.org/10.1016/S0002-9149(98)00007-1
Klein, Allan L. ; Asinger, Richard W. ; Black, Ian W. ; Davidoff, Ravin ; Erbel, Raimund ; Halperin, Jonathan L. ; Orsinelli, David A. ; Porter, Thomas R. ; Stoddard, Marcus F. ; Arheart, Kristopher ; Grimm, Richard A. ; Murray, R. Daniel. / Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study). In: American Journal of Cardiology. 1998 ; Vol. 81, No. 7. pp. 877-883.
@article{b0278b31af5044f5ac3db5f69059faf4,
title = "Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study)",
abstract = "Patients with atrial fibrillation (AF) undergoing cardioversion are at an increased risk of cardioembolic stroke and require anticoagulation. The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Multicenter Study is a randomized clinical trial of patients undergoing electrical cardioversion of AF of >2 days' duration comparing a transesophageal-guided strategy (TEE) with brief anticoagulation to the conventional anticoagulation strategy. Patients randomly assigned to the TEE- guided strategy receive therapeutic anticoagulation before TEE and cardioversion, followed by 4 weeks of anticoagulation. Patients with thrombus imaged by TEE have postponement of cardioversion, continue anticoagulation for 3 weeks, and undergo a repeat TEE. Conventional strategy patients receive 3 weeks of anticoagulation before cardioversion, followed by 4 weeks of anticoagulation after cardioversion. The primary end point events are ischemic stroke, transient ischemic attack, and systemic embolization for an 8-week period from enrollment. Secondary end points are major and minor bleeding, all-course mortality, successful return to and maintenance of sinus rhythm, and cost effectiveness. Analysis is based on the intention-to-treat principle. The anticipated rates of embolism of 2.9{\%} for conventional strategy and 1.2{\%} for the TEE-guided strategy are based on published research and the completed pilot study. The ACUTE Multicenter Study will randomize therapy and follow an estimated 3,000 patients from 65 study sites to determine the relative efficacy of the TEE-guided and conventional approaches to electrical cardioversion for patients in AF. The results of this investigation will have important clinical implications for the management of patients with AF undergoing electrical cardioversion.",
author = "Klein, {Allan L.} and Asinger, {Richard W.} and Black, {Ian W.} and Ravin Davidoff and Raimund Erbel and Halperin, {Jonathan L.} and Orsinelli, {David A.} and Porter, {Thomas R.} and Stoddard, {Marcus F.} and Kristopher Arheart and Grimm, {Richard A.} and Murray, {R. Daniel}",
year = "1998",
month = "4",
day = "1",
doi = "10.1016/S0002-9149(98)00007-1",
language = "English",
volume = "81",
pages = "877--883",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (the ACUTE Multicenter Study)

AU - Klein, Allan L.

AU - Asinger, Richard W.

AU - Black, Ian W.

AU - Davidoff, Ravin

AU - Erbel, Raimund

AU - Halperin, Jonathan L.

AU - Orsinelli, David A.

AU - Porter, Thomas R.

AU - Stoddard, Marcus F.

AU - Arheart, Kristopher

AU - Grimm, Richard A.

AU - Murray, R. Daniel

PY - 1998/4/1

Y1 - 1998/4/1

N2 - Patients with atrial fibrillation (AF) undergoing cardioversion are at an increased risk of cardioembolic stroke and require anticoagulation. The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Multicenter Study is a randomized clinical trial of patients undergoing electrical cardioversion of AF of >2 days' duration comparing a transesophageal-guided strategy (TEE) with brief anticoagulation to the conventional anticoagulation strategy. Patients randomly assigned to the TEE- guided strategy receive therapeutic anticoagulation before TEE and cardioversion, followed by 4 weeks of anticoagulation. Patients with thrombus imaged by TEE have postponement of cardioversion, continue anticoagulation for 3 weeks, and undergo a repeat TEE. Conventional strategy patients receive 3 weeks of anticoagulation before cardioversion, followed by 4 weeks of anticoagulation after cardioversion. The primary end point events are ischemic stroke, transient ischemic attack, and systemic embolization for an 8-week period from enrollment. Secondary end points are major and minor bleeding, all-course mortality, successful return to and maintenance of sinus rhythm, and cost effectiveness. Analysis is based on the intention-to-treat principle. The anticipated rates of embolism of 2.9% for conventional strategy and 1.2% for the TEE-guided strategy are based on published research and the completed pilot study. The ACUTE Multicenter Study will randomize therapy and follow an estimated 3,000 patients from 65 study sites to determine the relative efficacy of the TEE-guided and conventional approaches to electrical cardioversion for patients in AF. The results of this investigation will have important clinical implications for the management of patients with AF undergoing electrical cardioversion.

AB - Patients with atrial fibrillation (AF) undergoing cardioversion are at an increased risk of cardioembolic stroke and require anticoagulation. The Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) Multicenter Study is a randomized clinical trial of patients undergoing electrical cardioversion of AF of >2 days' duration comparing a transesophageal-guided strategy (TEE) with brief anticoagulation to the conventional anticoagulation strategy. Patients randomly assigned to the TEE- guided strategy receive therapeutic anticoagulation before TEE and cardioversion, followed by 4 weeks of anticoagulation. Patients with thrombus imaged by TEE have postponement of cardioversion, continue anticoagulation for 3 weeks, and undergo a repeat TEE. Conventional strategy patients receive 3 weeks of anticoagulation before cardioversion, followed by 4 weeks of anticoagulation after cardioversion. The primary end point events are ischemic stroke, transient ischemic attack, and systemic embolization for an 8-week period from enrollment. Secondary end points are major and minor bleeding, all-course mortality, successful return to and maintenance of sinus rhythm, and cost effectiveness. Analysis is based on the intention-to-treat principle. The anticipated rates of embolism of 2.9% for conventional strategy and 1.2% for the TEE-guided strategy are based on published research and the completed pilot study. The ACUTE Multicenter Study will randomize therapy and follow an estimated 3,000 patients from 65 study sites to determine the relative efficacy of the TEE-guided and conventional approaches to electrical cardioversion for patients in AF. The results of this investigation will have important clinical implications for the management of patients with AF undergoing electrical cardioversion.

UR - http://www.scopus.com/inward/record.url?scp=0032054316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032054316&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(98)00007-1

DO - 10.1016/S0002-9149(98)00007-1

M3 - Article

VL - 81

SP - 877

EP - 883

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -